Literature DB >> 20847561

Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C.

Ancha Baranova1, Mohammed H Jarrar, Maria Stepanova, Andrew Johnson, Nila Rafiq, Terry Gramlich, Vikas Chandhoke, Zobair M Younossi.   

Abstract

BACKGROUND: The pathogenic mechanisms of hepatic steatosis in hepatitis C (HCV) remain unclear. AIM: To assess the potential role of cytokines and adipokines in HCV-related steatosis and fibrosis.
METHODS: We profiled several adipokines, cytokines, and related soluble molecules in 99 HCV patients and analyzed their potential associations with hepatic steatosis and fibrosis.
RESULTS: Serum leptin and IL-1RA were significantly higher in HCV genotype 1 as compared to genotype 3. On the other hand, serum resistin, IL-8, IL-1B and sIL-6R, were significantly higher in HCV genotype 3. No differences were observed for adiponectin, visfatin, IL-6 and TNF-α. Regardless of HCV genotype, steatosis could be predicted by a combination of IL-8, IL-6, and sIL-6R/IL-6. When analysis was repeated for each of the genotypes, the reliability of models improved. Regardless of HCV genotype, moderate to severe fibrosis (Metavir score >F2), was predicted by IL-8 and resistin levels.
CONCLUSIONS: Analysis of adipocytokines associated with steatosis supports the hypothesis that steatogenic pathways differ in HCV genotype 3 from those infected with non-genotype 3 infections.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847561     DOI: 10.1159/000314592

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  11 in total

1.  Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Authors:  S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens
Journal:  Aliment Pharmacol Ther       Date:  2015-08-28       Impact factor: 8.171

Review 2.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

3.  The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B.

Authors:  Enver Yüksel; Erdem Akbal; Erdem Koçak; Ömer Akyürek; Seyfettin Köklü; Fuat Ekiz; Barış Yılmaz
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

4.  Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C.

Authors:  Kamila Wójcik; Elżbieta Jabłonowska; Aleksandra Omulecka; Anna Piekarska
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 5.  Metabolic alterations and hepatitis C: From bench to bedside.

Authors:  Ming-Ling Chang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

6.  Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms.

Authors:  Ming-Ling Chang; Kung-Hao Liang; Cheng-Lung Ku; Chia-Chi Lo; Ya-Ting Cheng; Chen-Ming Hsu; Chau-Ting Yeh; Cheng-Tang Chiu
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

7.  Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).

Authors:  Cordelia Manickam; Lynn Wachtman; Amanda J Martinot; Luis D Giavedoni; R Keith Reeves
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

8.  Inflammasome Genes' Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment.

Authors:  Shady Z K Estfanous; Sahar A Ali; Sameh M Seif; Sameh H A Soror; Dalia H A Abdelaziz
Journal:  Mediators Inflamm       Date:  2019-01-09       Impact factor: 4.711

9.  Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure.

Authors:  Yu-Bao Zheng; Xiao-Hong Zhang; Zhan-Lian Huang; Chao-Shuang Lin; Jing Lai; Yu-Rong Gu; Bin-Liang Lin; Dong-Ying Xie; Shi-Bin Xie; Liang Peng; Zhi-Liang Gao
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.

Authors:  Michał Kukla; Marzena Zalewska-Ziob; Brygida Adamek; Janusz Kasperczyk; Rafał J Bułdak; Tomasz Sawczyn; Dominika Stygar; Barbara Sobala-Szczygieł; Marta Stachowska; Andrzej Gabriel; Andrzej Wiczkowski
Journal:  Clin Exp Hepatol       Date:  2019-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.